GEP20001940B - Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment - Google Patents

Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Info

Publication number
GEP20001940B
GEP20001940B GEAP19963845A GEAP1996003845A GEP20001940B GE P20001940 B GEP20001940 B GE P20001940B GE AP19963845 A GEAP19963845 A GE AP19963845A GE AP1996003845 A GEAP1996003845 A GE AP1996003845A GE P20001940 B GEP20001940 B GE P20001940B
Authority
GE
Georgia
Prior art keywords
treatment
processes
producing
crystalline form
anhydrous crystalline
Prior art date
Application number
GEAP19963845A
Other languages
English (en)
Inventor
James Wotrap David
David Michael Skinner
Philip George Lake
Gregory Alan Conway
William Bayne Grubb Iii
Richard Augustus Winnike
Peter Gregory Varlashkin
Jane Muse Partin
Barry Howard Carter
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20001940(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of GEP20001940B publication Critical patent/GEP20001940B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
GEAP19963845A 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment GEP20001940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
GEP20001940B true GEP20001940B (en) 2000-02-05

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19963845A GEP20001940B (en) 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Country Status (40)

Country Link
US (1) US6107302A (index.php)
EP (1) EP0804436B1 (index.php)
JP (1) JP3176633B2 (index.php)
KR (1) KR100376074B1 (index.php)
CN (1) CN1049893C (index.php)
AP (1) AP662A (index.php)
AR (1) AR002270A1 (index.php)
AT (1) ATE302777T1 (index.php)
AU (1) AU702794B2 (index.php)
BG (1) BG63393B1 (index.php)
BR (1) BR9606768A (index.php)
CA (1) CA2210799C (index.php)
CY (1) CY2531B1 (index.php)
CZ (1) CZ297065B6 (index.php)
DE (1) DE69635106T2 (index.php)
DK (1) DK0804436T3 (index.php)
EA (1) EA000364B1 (index.php)
EE (1) EE03528B1 (index.php)
ES (1) ES2248806T3 (index.php)
FI (1) FI973063A7 (index.php)
GB (1) GB9501178D0 (index.php)
GE (1) GEP20001940B (index.php)
HR (1) HRP960024B1 (index.php)
HU (1) HU222993B1 (index.php)
IL (1) IL116831A (index.php)
IN (1) IN182468B (index.php)
IS (1) IS2268B (index.php)
NO (1) NO315558B1 (index.php)
NZ (1) NZ298851A (index.php)
OA (1) OA10499A (index.php)
PL (1) PL182175B1 (index.php)
RO (1) RO118693B1 (index.php)
RS (1) RS49518B (index.php)
SI (1) SI0804436T1 (index.php)
SK (1) SK285329B6 (index.php)
TR (1) TR199700656T1 (index.php)
UA (1) UA46001C2 (index.php)
UY (1) UY25779A1 (index.php)
WO (1) WO1996022291A1 (index.php)
ZA (1) ZA96449B (index.php)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
DE50209483D1 (de) * 2001-02-24 2007-03-29 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
CA2457835A1 (en) * 2001-09-07 2003-03-20 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
NZ600394A (en) * 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
PH12012502162A1 (en) 2010-05-05 2013-02-04 Boehringer Ingelheim Int Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP2585101A1 (en) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EP0804436A1 (en) 1997-11-05
NO973326L (no) 1997-09-16
ZA96449B (en) 1996-08-07
JP3176633B2 (ja) 2001-06-18
ATE302777T1 (de) 2005-09-15
EE9700175A (et) 1998-02-16
HUP9801836A3 (en) 1999-06-28
GB9501178D0 (en) 1995-03-08
KR100376074B1 (ko) 2003-06-02
NO315558B1 (no) 2003-09-22
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
IS2268B (is) 2007-07-15
KR19980701525A (ko) 1998-05-15
AP9701058A0 (en) 1997-10-31
EA000364B1 (ru) 1999-06-24
BR9606768A (pt) 1997-12-30
PL182175B1 (pl) 2001-11-30
US6107302A (en) 2000-08-22
AU4453996A (en) 1996-08-07
FI973063L (fi) 1997-09-18
AP662A (en) 1998-08-19
MX9705462A (es) 1997-10-31
CZ297065B6 (cs) 2006-08-16
CA2210799C (en) 2008-06-10
NO973326D0 (no) 1997-07-18
DE69635106T2 (de) 2006-06-08
SK96597A3 (en) 1998-02-04
ES2248806T3 (es) 2006-03-16
NZ298851A (en) 1999-01-28
RO118693B1 (ro) 2003-09-30
UA46001C2 (uk) 2002-05-15
HUP9801836A2 (hu) 1999-05-28
PL321326A1 (en) 1997-12-08
DE69635106D1 (de) 2005-09-29
CY2531B1 (en) 2006-04-12
UY25779A1 (es) 2000-08-21
EP0804436B1 (en) 2005-08-24
IL116831A0 (en) 1996-05-14
RS49518B (sr) 2006-10-27
JPH11503718A (ja) 1999-03-30
HRP960024A2 (en) 1997-10-31
WO1996022291A1 (en) 1996-07-25
IN182468B (index.php) 1999-04-17
FI973063A0 (fi) 1997-07-18
FI973063A7 (fi) 1997-09-18
IL116831A (en) 1998-10-30
IS4527A (is) 1997-07-15
EA199700124A1 (ru) 1997-12-30
OA10499A (en) 2002-04-10
YU3396A (sh) 1998-12-23
HRP960024B1 (en) 2005-08-31
EE03528B1 (et) 2001-10-15
AU702794B2 (en) 1999-03-04
HU222993B1 (hu) 2004-01-28
CN1179159A (zh) 1998-04-15
TR199700656T1 (xx) 1998-03-21
DK0804436T3 (da) 2005-12-27
CA2210799A1 (en) 1996-07-25
SK285329B6 (sk) 2006-11-03
BG101833A (bg) 1998-04-30
CZ229497A3 (en) 1997-12-17
AR002270A1 (es) 1998-03-11
SI0804436T1 (sl) 2006-02-28

Similar Documents

Publication Publication Date Title
GEP20001940B (en) Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment
CA2213339A1 (en) Method of treating adenosine depletion
HU913396D0 (en) Process for the production of azasteroide compounds and medical preparations containing them as active agents
MY114132A (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
DE69329887D1 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
IL111257A0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
IL106936A0 (en) Substituted cyclohexane derivatives,processes for their preparation and the use of the compounds for treating diseases
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
ES8304969A1 (es) Procedimiento para la obtencion de 2-aril-3,4-diazabiciclo 4.n.0-alq-2-en-5-onas.
ES8503643A1 (es) Un procedimiento para la preparacion de compuestos de bis (carboxamida)
IL85932A (en) 1-pyridyl (or pyrimidyl)-4-diphenylbutyl piperazines, process for their preparation and pharmaceutical compositions containing them
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
FR2651769B1 (fr) Procede de traitement, par fermentation anaerobie, d'eaux residuaires en vue de l'elimination de la matiere organique et des sulfates qu'elles contiennent.
DE69103087D1 (de) N-substituierte Trifluormethylphenyltetrahydropyridine, Verfahren zur Herstellung, Zwischenprodukte, sowie Arzneimittel, die solche enthalten.
MD1687G2 (ro) Compuşi ariltio, compoziţie farmaceutică, metode de tratament al infecţiilor bacteriene şi virale
HUT45250A (en) Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
FR2682950B1 (fr) Procede d'elimination de la diethanolamine presente dans la triethanolamine et procede de preparation de triethanolamine purifiee.
GR900100332A (en) Process for preparation of phenoxypropanolamines pharmaceutical compositions containing them and their use as antiobesity agents
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
GR1002251B (en) Process for preparing clystalline (5r,6s)-2-carbamouloxymethyl-6-£(1r)-hydroxyethyl|-2-penem-carboxylic acid and its pharmaceutical formulation
GR3036868T3 (en) Amino alcohol derivatives, methods of producing said derivatives and medicaments containing them